Gates Foundation’s CureVac CVAC Stock Holding History

Gates Foundation’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$4.61M	Sell	1,568,866 -28,771	-2%	-$94.8K	10.6%	4
2024 Q2	$5.43M	Hold	1,597,637	–	–	13.51%	4
2024 Q1	$6.71M	Sell	1,597,637 -28,306	-2%	-$99.4K	7.98%	5
2023 Q4	$6.83M	Hold	1,625,943	–	–	7.6%	5
2023 Q3	$11.1M	Hold	1,625,943	–	–	13.24%	4
2023 Q2	$16.9M	Hold	1,625,943	–	–	13.48%	3
2023 Q1	$11.3M	Hold	1,625,943	–	–	10.01%	4
2022 Q4	$9.8M	Sell	1,625,943 -83,838	-5%	-$619K	7.55%	5
2022 Q3	$13.5M	Hold	1,709,781	–	–	10.67%	5
2022 Q2	$23.3M	Hold	1,709,781	–	–	17.91%	2
2022 Q1	$33.5M	Sell	1,709,781 -1,424,999	-45%	-$28.5M	18.01%	2
2021 Q4	$108M	Hold	3,134,780	–	–	32.65%	1
2021 Q3	$171M	Hold	3,134,780	–	–	50.12%	1
2021 Q2	$230M	Hold	3,134,780	–	–	35.34%	2
2021 Q1	$287M	Hold	3,134,780	–	–	46.92%	1
2020 Q4	$254M	Buy	+3,134,780	New	+$240M	58.02%	1

Other funds holding CVAC

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Gates Foundation's CVAC Position: Q3 2024 in Review

Gates Foundation reduced its CureVac (CVAC) stake by 1.8% in Q3 2024, selling an estimated $94.8K and leaving 1,568,866 shares worth $4.61M. The position accounts for 10.6% of the portfolio, ranked #4.

Gates Foundation first reported a position in CVAC in Q4 2020 and has held it in 16 quarters since. The position peaked at $287M in Q1 2021. 81 funds tracked by Wall St. Rank hold CVAC as of Q3 2024.

Gates Foundation held 1,568,866 shares of CureVac worth $4.61M as of Q3 2024.
Gates Foundation sold 28,771 CureVac shares in Q3 2024, an estimated $94.8K.
CureVac made up 10.6% of Gates Foundation's portfolio in Q3 2024, its #4 holding.
Gates Foundation first reported a position in CureVac in Q4 2020 and has held it in 16 quarters since.
Gates Foundation's CureVac position peaked at $287M in Q1 2021.
81 funds tracked by Wall St. Rank held CureVac as of Q3 2024.

Based on Gates Foundation's 13F filing for Q3 2024, filed 14 Nov 2024.